Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Other Non Operating Income (2019 - 2025)

Benitec Biopharma has reported Other Non Operating Income over the past 7 years, most recently at $19000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at $19000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$196000.0 (down 492.0% YoY), and the annual figure for FY2025 was -$71000.0, changed.
  • Other Non Operating Income reached $19000.0 in Q4 2025 per BNTC's latest filing, up from -$89000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $229000.0 in Q1 2022 and bottomed at -$507000.0 in Q3 2022.
  • Median Other Non Operating Income over the past 5 years was -$34500.0 (2023), compared with a mean of -$57642.9.
  • Peak annual rise in Other Non Operating Income hit 380.0% in 2021, while the deepest fall reached 988.89% in 2021.
  • Over 5 years, Other Non Operating Income stood at $48000.0 in 2021, then grew by 4.17% to $50000.0 in 2022, then surged by 204.0% to $152000.0 in 2023, then tumbled by 67.11% to $50000.0 in 2024, then crashed by 62.0% to $19000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for BNTC at $19000.0 in Q4 2025, -$89000.0 in Q3 2025, and -$126000.0 in Q2 2025.